Pharma giant moving Pa. headquarters to N.J., creating hundreds of jobs - lehighvalleylive.com
13 Teva : Top 25 Pharma & BioPharma in 2018 - Contract Pharma
Teva Announces New Brand Positioning and Visual Identity in North America
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ANJL4AXVTBOMDKS2X4DIJZXZAY.jpg "Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters")
Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters
A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New York Times
Buffett's Berkshire adds to Teva stake in the first quarter
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New York Times
Teva Pharmaceutical reports Q1 2018 | AlphaStreet
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Industries (NYSE:TEVA) Seems To Be Using A Lot Of Debt - Simply Wall St News
Teva Pharmaceuticals soars after Warren Buffett's Berkshire Hathaway discloses a stake (TEVA) | Markets Insider
Teva down as it reports lower sales and profit for 2018
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets | News Direct
Teva: Great Investment With An Upside Even In Volatile Markets (NYSE:TEVA) | Seeking Alpha
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
14. Teva Pharmaceutical Industries | FiercePharma
Will Teva Stock Rebound After A 10% Fall In A Month?
Teva Pharmaceutical Industries: Teva Pharm raises 2018 profit outlook, sees strong migraine drug launch, Health News, ET HealthWorld
Teva Pharmaceutical Industries and opioid settlement: What to know
Teva Narrows Losses in 2019 – Business News From Israel
Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug | BioSpace
Teva Pharmaceutical falls 6% on eve of Q3 earnings show | Seeking Alpha
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
